Aktie A3DFKH LARR HEALPAR
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen LARR HEALPAR

Aktien

A3DFKH

US51724W1071

LSPR

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Larkspur Acquisition Completes Merger With ZyVersa Therapeutics
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")
Larkspur Health Acquisition Corp.(NasdaqGM:LSPR) dropped from NASDAQ Composite Index
Larkspur Health Acquisition Corp. announced that it has received $8.635 million in funding
ZyVersa Therapeutics, Inc. completed the acquisition of Larkspur Health Acquisition Corp. from Larkspur Health LLC, A.G.P. / Alliance Global Partners Corp. and others in a reverse merger transaction.
LARKSPUR HEALTH ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
Larkspur Health Acquisition Corp. has Changed its Name to ZyVersa Therapeutics, Inc
ZyVersa Therapeutics' CEO, Stephen C. Glover, and CCO, Karen A. Cashmere, Are Invited Speakers at the 4th Inflammasome Therapeutics Summit
SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Larkspur Health Acquisition Corp., Inc. with ZyVersa Therapeutics, Inc.
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Larkspur Health Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is Invited Speaker at BioFlorida 2022 Annual Conference
Larkspur Health Acquisition Refiles Registration Statement for Business Combination Agreement With ZyVersa Therapeutics
ZyVersa Therapeutics and Larkspur Health Acquisition Corp. Announce Business Combination, Interim Financing and PIPE Investment Update
Data Published in Frontiers in Molecular Neuroscience Demonstrate That ZyVersa's Inflammasome ASC Inhibitor, IC 100, Is Effective in Reducing Brain Inflammation in a Preclinical Model of Aging
LARKSPUR HEALTH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Larkspur Health Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Larkspur Health Acquisition Corp. Files Registration Statement on Form S-4 Regarding the Proposed Business Combination with ZyVersa Therapeutics
ZyVersa's Proprietary Inflammasome ASC Inhibitor's Differentiated Mechanism of Action Featured in Translational Research Paper
Larkspur Health Acquisition : ZyVersa Therapeutics to Become a Publicly Traded Biopharma Company via Merger with Larkspur Health Acquisition Corp - Form 8-K
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DFKH Aktie
  4. Nachrichten LARR HEALPAR
  5. Andere Sprachen
-40 % Einmalige Verlängerung: Unsere Abonnements führen Sie zu den besten Investitionen von morgen
PROFITIEREN SIE JETZT